Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, par value $0.001 per share · CUSIP: 05338F306
Event date: 2026-01-28
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Millennium Management LLC
Shares: 905,798.00 · Class: 4.9%
- Millennium Group Management LLC
Shares: 905,798.00 · Class: 4.9%
- Israel A. Englander
Shares: 905,798.00 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-009818
- Form type
- SCHEDULE 13G
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Feb 03, 2026
- Reporting period
- Jan 28, 2026
- Description
- Schedule 13G beneficial ownership